PE20150154A1 - N-[4-(quinolin-4-iloxi)ciclohexil(metil)](hetero)arilcarboxamidas como antagonistas del receptor de androgenos, su produccion y usos como productos medicinales - Google Patents
N-[4-(quinolin-4-iloxi)ciclohexil(metil)](hetero)arilcarboxamidas como antagonistas del receptor de androgenos, su produccion y usos como productos medicinalesInfo
- Publication number
- PE20150154A1 PE20150154A1 PE2014002495A PE2014002495A PE20150154A1 PE 20150154 A1 PE20150154 A1 PE 20150154A1 PE 2014002495 A PE2014002495 A PE 2014002495A PE 2014002495 A PE2014002495 A PE 2014002495A PE 20150154 A1 PE20150154 A1 PE 20150154A1
- Authority
- PE
- Peru
- Prior art keywords
- cyclohexil
- methyl
- iloxi
- arylcarboxamides
- quinolin
- Prior art date
Links
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 title abstract 2
- 229940123407 Androgen receptor antagonist Drugs 0.000 title 1
- 239000003936 androgen receptor antagonist Substances 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102000001307 androgen receptors Human genes 0.000 abstract 1
- 108010080146 androgen receptors Proteins 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Quinoline Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Apparatus For Radiation Diagnosis (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE N-[4-(QUINOLIN-4-ILOXI)CICLOHEXIL(METIL)](HETERO)ARILCARBOXAMIDAS DE FORMULA (I) DONDE R1, A Y n SON COMO SE DEFINEN EN LA DESCRIPCION. SON COMPUESTOS PREFERIDOS: N-({TRANS-4-[(8-FLUOROQUINOLIN-4-IL)OXI]CICLOHEXIL}METIL)-4-FLUOROBENZAMIDA; N-{TRANS-4-[(8-BROMOQUINOLIN-4-IL)OXI]CICLOHEXIL}-5-METILISOXAZOL-3-CARBOXAMIDA; ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR DE ANDROGENOS SIENDO UTILES EN EL TRATAMIENTO DE ENFERMEDADES HIPERPROLIFERATIVAS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12004764 | 2012-06-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20150154A1 true PE20150154A1 (es) | 2015-02-19 |
Family
ID=48699019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2014002495A PE20150154A1 (es) | 2012-06-26 | 2013-06-24 | N-[4-(quinolin-4-iloxi)ciclohexil(metil)](hetero)arilcarboxamidas como antagonistas del receptor de androgenos, su produccion y usos como productos medicinales |
Country Status (40)
| Country | Link |
|---|---|
| US (1) | US9428460B2 (es) |
| EP (1) | EP2864291B1 (es) |
| JP (1) | JP6181172B2 (es) |
| KR (1) | KR20150023880A (es) |
| AP (1) | AP3919A (es) |
| AR (1) | AR091565A1 (es) |
| AU (1) | AU2013283543B2 (es) |
| BR (1) | BR112014032538A2 (es) |
| CA (1) | CA2877786C (es) |
| CL (1) | CL2014003443A1 (es) |
| CO (1) | CO7170167A2 (es) |
| CR (1) | CR20140593A (es) |
| CU (1) | CU20140144A7 (es) |
| CY (1) | CY1118412T1 (es) |
| DK (1) | DK2864291T3 (es) |
| DO (1) | DOP2014000295A (es) |
| EA (1) | EA028063B1 (es) |
| EC (1) | ECSP14032516A (es) |
| ES (1) | ES2609455T3 (es) |
| HR (1) | HRP20161745T1 (es) |
| HU (1) | HUE032306T2 (es) |
| IL (1) | IL236146B (es) |
| JO (1) | JO3342B1 (es) |
| LT (1) | LT2864291T (es) |
| MA (1) | MA37700B1 (es) |
| ME (1) | ME02590B (es) |
| MX (1) | MX2014016054A (es) |
| NZ (1) | NZ703100A (es) |
| PE (1) | PE20150154A1 (es) |
| PH (1) | PH12014502869B1 (es) |
| PL (1) | PL2864291T3 (es) |
| PT (1) | PT2864291T (es) |
| RS (1) | RS55500B1 (es) |
| SG (1) | SG11201408254UA (es) |
| SI (1) | SI2864291T1 (es) |
| TN (1) | TN2014000532A1 (es) |
| TW (1) | TWI600646B (es) |
| UA (1) | UA115447C2 (es) |
| UY (1) | UY34881A (es) |
| WO (1) | WO2014001247A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015164374A1 (en) * | 2014-04-22 | 2015-10-29 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| UY36391A (es) * | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen |
| TWI726969B (zh) | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物 |
| JP2019519485A (ja) * | 2016-05-04 | 2019-07-11 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | インドールアミン２，３−ジオキシゲナーゼ阻害剤およびその使用方法 |
| JP2019516687A (ja) | 2016-05-04 | 2019-06-20 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | インドールアミン２，３−ジオキシゲナーゼ阻害剤およびその使用方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5328821A (en) | 1991-12-12 | 1994-07-12 | Robyn Fisher | Cold and cryo-preservation methods for human tissue slices |
| US6566372B1 (en) | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
| CA2413579A1 (en) | 2000-06-23 | 2002-01-03 | Eli Lilly And Company | Methods and compounds for inhibiting mrp1 |
| KR100883731B1 (ko) | 2001-06-22 | 2009-02-12 | 기린 파마 가부시끼가이샤 | 간세포 증식 인자 수용체 자기 인산화를 저해하는 퀴놀린유도체 및 퀴나졸린 유도체 및 이들을 함유하는 의약 조성물 |
| KR100863667B1 (ko) | 2002-09-11 | 2008-10-15 | 가부시끼가이샤 구레하 | 아민 화합물 및 그 용도 |
| US20050227932A1 (en) | 2002-11-13 | 2005-10-13 | Tianbao Lu | Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction |
| EP1590334B1 (en) | 2003-01-30 | 2009-08-19 | Boehringer Ingelheim Pharmaceuticals Inc. | 2,4-diaminopyrimidine derivatives useful as inhibitors of pkc-theta |
| SE0302573D0 (sv) | 2003-09-26 | 2003-09-26 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| JP2007529511A (ja) | 2004-03-17 | 2007-10-25 | グラクソ グループ リミテッド | Ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト |
| SE0401342D0 (sv) | 2004-05-25 | 2004-05-25 | Astrazeneca Ab | Therapeutic compounds |
| WO2005117570A1 (en) | 2004-05-27 | 2005-12-15 | Jack Saffron | Feeding dish to prevent pest infestation |
| WO2006052722A1 (en) | 2004-11-09 | 2006-05-18 | Smithkline Beecham Corporation | Glycogen phosphorylase inhibitor compounds and pharmaceutical compositions thereof |
| JO2787B1 (en) * | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| GB0509227D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Intracellular enzyme inhibitors |
| GB0509224D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Inhibitors of intracellular enzymatic activity |
| US20060293341A1 (en) | 2005-06-23 | 2006-12-28 | Vrej Jubian | Alkyl sulfonamide derivatives |
| KR20080100238A (ko) | 2006-02-06 | 2008-11-14 | 쇼와 덴코 가부시키가이샤 | 미백 피부 외용제 |
| JP2009539878A (ja) | 2006-06-08 | 2009-11-19 | アレイ バイオファーマ、インコーポレイテッド | キノリン化合物および使用方法 |
| GB0619753D0 (en) | 2006-10-06 | 2006-11-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| WO2008064432A1 (en) | 2006-12-01 | 2008-06-05 | The University Of Sydney | Polycyclic molecular compounds |
| US8377949B2 (en) | 2007-08-16 | 2013-02-19 | Boehringer Ingelheim International Gmbh | Quinazolinedione chymase inhibitors |
| US8680291B2 (en) * | 2007-10-26 | 2014-03-25 | The Regents Of The University Of California | Diarylhydantoin compounds |
| JP5699075B2 (ja) | 2008-05-14 | 2015-04-08 | アムジエン・インコーポレーテツド | 癌の治療のためのｖｅｇｆ（ｒ）阻害剤および肝細胞増殖因子（ｃ−ｍｅｔ）阻害剤との組合せ |
| WO2010039248A1 (en) | 2008-10-01 | 2010-04-08 | Ludwig Institute For Cancer Research | Methods for the treatment of cancer |
| NZ597528A (en) | 2009-07-21 | 2014-08-29 | Gilead Sciences Inc | Inhibitors of flaviviridae viruses |
| US20120238533A1 (en) | 2009-09-11 | 2012-09-20 | Bayer Pharma Aktiengesellschaft | (Heteroarylmethyl) Thiohydantoins as anticancer drugs |
| PT2592933T (pt) | 2010-07-16 | 2017-05-23 | Gaweco Anderson | Inibidores de mif e suas utilizações |
-
2013
- 2013-06-24 BR BR112014032538A patent/BR112014032538A2/pt not_active Application Discontinuation
- 2013-06-24 LT LTEP13731325.0T patent/LT2864291T/lt unknown
- 2013-06-24 EP EP13731325.0A patent/EP2864291B1/en active Active
- 2013-06-24 MA MA37700A patent/MA37700B1/fr unknown
- 2013-06-24 EA EA201500039A patent/EA028063B1/ru not_active IP Right Cessation
- 2013-06-24 KR KR20157001996A patent/KR20150023880A/ko not_active Ceased
- 2013-06-24 PL PL13731325T patent/PL2864291T3/pl unknown
- 2013-06-24 ME MEP-2016-292A patent/ME02590B/me unknown
- 2013-06-24 JP JP2015519023A patent/JP6181172B2/ja not_active Expired - Fee Related
- 2013-06-24 HU HUE13731325A patent/HUE032306T2/en unknown
- 2013-06-24 AP AP2014008141A patent/AP3919A/en active
- 2013-06-24 UA UAA201500561A patent/UA115447C2/uk unknown
- 2013-06-24 NZ NZ703100A patent/NZ703100A/en not_active IP Right Cessation
- 2013-06-24 WO PCT/EP2013/063118 patent/WO2014001247A1/en not_active Ceased
- 2013-06-24 SI SI201330440A patent/SI2864291T1/sl unknown
- 2013-06-24 JO JOP/2013/0192A patent/JO3342B1/ar active
- 2013-06-24 ES ES13731325.0T patent/ES2609455T3/es active Active
- 2013-06-24 PT PT137313250T patent/PT2864291T/pt unknown
- 2013-06-24 RS RS20161149A patent/RS55500B1/sr unknown
- 2013-06-24 PE PE2014002495A patent/PE20150154A1/es active IP Right Grant
- 2013-06-24 AU AU2013283543A patent/AU2013283543B2/en not_active Ceased
- 2013-06-24 SG SG11201408254UA patent/SG11201408254UA/en unknown
- 2013-06-24 HR HRP20161745TT patent/HRP20161745T1/hr unknown
- 2013-06-24 US US14/408,876 patent/US9428460B2/en not_active Expired - Fee Related
- 2013-06-24 MX MX2014016054A patent/MX2014016054A/es unknown
- 2013-06-24 DK DK13731325.0T patent/DK2864291T3/en active
- 2013-06-24 CA CA2877786A patent/CA2877786C/en not_active Expired - Fee Related
- 2013-06-26 UY UY0001034881A patent/UY34881A/es not_active Application Discontinuation
- 2013-06-26 TW TW102122775A patent/TWI600646B/zh not_active IP Right Cessation
- 2013-06-26 AR ARP130102253 patent/AR091565A1/es unknown
-
2014
- 2014-12-09 IL IL236146A patent/IL236146B/en active IP Right Grant
- 2014-12-18 CU CUP2014000144A patent/CU20140144A7/es unknown
- 2014-12-18 CL CL2014003443A patent/CL2014003443A1/es unknown
- 2014-12-18 CR CR20140593A patent/CR20140593A/es unknown
- 2014-12-19 CO CO14279115A patent/CO7170167A2/es unknown
- 2014-12-19 EC ECIEPI201432516A patent/ECSP14032516A/es unknown
- 2014-12-19 DO DO2014000295A patent/DOP2014000295A/es unknown
- 2014-12-22 PH PH12014502869A patent/PH12014502869B1/en unknown
- 2014-12-25 TN TN2014000532A patent/TN2014000532A1/fr unknown
-
2016
- 2016-12-23 CY CY20161101343T patent/CY1118412T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201591087A1 (ru) | Новые производные бензимидазола в качестве антагонистов рецептора ep4 | |
| UY33483A (es) | Acidos de hidroxifenilhexinoico ariloxialquileno-sustituido, procedimiento para su preparacion y su uso como medicamento. | |
| CY1118678T1 (el) | Παραγωγα καρβοξαμιδιου χλωρο-πυραζινης χρησιμα για την θεραπευτικη αντιμετωπιση ασθενειων που ευνοουνται απο την ανεπαρκη ενυδατωση του βλεννογονου | |
| UY35012A (es) | Alcoxipirazoles como activadores de guanilato ciclasa soluble | |
| EA201501122A1 (ru) | Новые агонисты соматостатиновых рецепторов подтипа 4 (sstr4) | |
| EA201491028A1 (ru) | Способ получения замещенных 5-фтор-1н-пиразолопиридинов | |
| NI201500050A (es) | Benzamidas | |
| CO2018007278A2 (es) | Derivados de ácido aminobenzoico metaazacíclico como antagonistas de la integrina pan | |
| CY1121063T1 (el) | Αναστολεις της συνθασης της αλδοστερονης | |
| PE20142450A1 (es) | Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1 | |
| PE20150154A1 (es) | N-[4-(quinolin-4-iloxi)ciclohexil(metil)](hetero)arilcarboxamidas como antagonistas del receptor de androgenos, su produccion y usos como productos medicinales | |
| EA201400623A1 (ru) | Новые 2h-индазолы в качестве антагонистов рецептора ep | |
| UA117154C2 (uk) | Антагоністи s1p3 | |
| CU20120087A7 (es) | Procedimiento de síntesis y forma cristalina del hidrocloruro de 4-(3-(cis-hexahidrociclopenta(c)pirrol-2(1h)-il)propoxi)benzamida así como las composiciones farmacéuticas que la contienen | |
| EA201391742A1 (ru) | Фармацевтическая композиция, включающая фексофенадин | |
| MX2015006807A (es) | Metodo de preparacion de formas cristalinas de la 4-(ciclopropilmetoxi)-n-(3,5-dicloro-1-oxidopiridin-4-il)-5-metox ipiridin-2-carboxamida y sus formas cristalinas. | |
| MX2016010549A (es) | Indol- y bencimidazolcarboxamidas como insecticidas y acaricidas. | |
| UY35743A (es) | Procedimiento de síntesis para la preparación de analogos c1-ceto macrociclicos de halicondrina b e intermediarios útiles en el mismo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |